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Abstract 
 
This article sketches open innovation strategies pursued by eight Indian pharmaceutical 
firms and provides an account of strategic flexibility charted by firms in the wake of 
changes in the legislative environment. The findings examined through the lens of open 
innovation and dynamic capabilities identifies Ôtechnological competenciesÕ and 
ÔfundingÕ as two very important reasons, which push the traditionally closed R&D firms 
to pursue open innovation. Within the dynamic capabilities framework, the findings 
suggest that resources and competencies play a vital role in enabling open innovation in 
the complex new drug research setting.  
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Introduction  
The national environment in India for the pharmaceutical sector underwent changes 
post 2005 following the implementation of Trade-Related Aspects of Intellectual 
Property Rights (TRIPS) agreement, which resulted in a change in the legislative 
environment. India extended the product patent recognition in the area of 
pharmaceuticals, marking a significant transition point for the pharmaceutical industry, 
heavily dependent on generic business. The change in patent regime aimed to mark a 
shift from incremental innovation towards more substantial innovation. The purpose of 
this article is to a) examine the open innovation strategies pursued by Indian 
pharmaceutical firms to undertake new drug innovation b) to understand what factors 
influence their strategic choices. This paper views open innovation strategies pursued 
by firms in the context of firmÕs current resources and competencies through a dynamic 
capabilities lens.  
 
Theoretical Background 
 
Adaptive Open Innovation Strategies 
The theoretical background is reviewed covering literature on innovation, open 
innovation and dynamic capabilities. The open innovation approach (Chesbrough, 
2003b) rests on the underlying argument, that the traditional in-house R&D structure is 
losing ground in the wake of revolutionary factors like globalization of technology, 
resources, knowledge, and funds defining new ways in, which innovation is taking 
place (Chesbrough, 2003b, Chesbrough and Crowther, 2006). Firms differ in how they 
pursue open innovation (MacKinven et al., 2014), the inbound open strategy allows 
firms to exploit discoveries of others in their own R&D labs while the outbound open 
innovation strategy allows firm to opt for external pathways to exploit their innovation 
(Chesbrough and Crowther, 2006, Chesbrough, 2003a). This classification was 
extended to include the Ôcoupled processÕ, which integrates outside-in and inside-out 
processes by aligning with complementary partners (Gassmann and Enkel, 2004, Enkel 
et al., 2009). The table below summarizes the open innovation strategies used in 
pharmaceutical sector by various authors. 
 
Table 1: Open Innovation strategies in pharmaceutical sector 
Open Innovation Strategies Industry/Sector Study 
In-licensing Internationalization of 
R&D 
 
Pharmaceuticals 
/Biotechnology 
(Enkel et al., 2009, 
Gassmann, 2006, 
Arora et al., 2009, 
Getz, 2011, 
Cockburn and 
Henderson, 1996, 
Chesbrough, 
2003b) 
Collaborative 
Innovation 
Firm-centric network with 
offshore outposts 
Across range of R&D 
companies 
(Jelinek et al., 
2012) 
 Bidirectional Information 
exchange 
Transfer of basic 
knowledge from public 
funded institutions to firms 
 
Pharmaceutical firms (Cockburn and 
Henderson, 1996) 
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 Industry wide, targeted, 
collaborative innovation 
efforts 
Across range of R&D 
companies 
(Jelinek et al., 
2012) 
 Public private partnerships 
for neglected diseases 
Modular approach to R&D 
 
Neglected diseases (London School of 
Economics and 
Political Science, 
2005) 
 Virtual, ad hoc networks 
of resources.   
Drug R&D (Jelinek et al., 
2012) 
 Open Source Model in 
drug discovery  
New drugs (rdal and 
R¿ttingen, 2012) 
Out-licensing External 
commercialization of 
intellectual property 
Pharmaceuticals 
/Biotechnology 
(Chesbrough, 2006, 
Rothaermel and 
Deeds, 2004, 
Grootendorst, 2009, 
Lichtenthaler, 
2007) 
 
 
Dynamic Capabilities Perspective 
The resource-based view as key approach to strategy formulation and a way to attain 
competitive advantage found various endorsers in the strategic management literature 
(Regnr and Zander, 2011, Barney, 2001, Hansen and Nohria, 2004, Peteraf, 1993, 
Wernerfelt, 1984, Wright, 1994). Dynamic capabilities framework defines a firmÕs 
ÔpositionÕ as Ôcurrent specific endowments of technology, intellectual property, 
complementary assets, customer base and its external relations with suppliers and 
complementorsÕ(Teece et al., 1997, p 518). Two important pillars of the dynamic 
capabilities framework are: a) the firmÕs resource ÔpositionÕ in shaping boundary 
decisions b) the firmÕs ability to change in a changing environment context (Teece et 
al., 1997).  As innovation represents a high degree of change and uncertainty, dynamic 
capabilities is an essential component of the innovation process (Lee and Kelley, 2008).  
 
Conceptual Framework 
The conceptual framework is a congruence of two bodies of literature, dynamic 
capabilities approach and open innovation. The focus of the study is to understand the 
influence of firm position (resources and competencies) in pushing firms to follow open 
innovation strategies (in-licensing, out-licensing and collaborative R&D) in changing 
contextual conditions. The scope of the study is new drug innovation in the Indian 
pharmaceutical industry. 
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Figure 1- Conceptual framework, synthesized from (Chesbrough et al., 2006, Chesbrough, 
2003b, Enkel et al., 2009, Gassmann, 2006, Teece et al., 1997, Teece, 2009) 
 
The main research questions are: 
a) How has the product patent regime influenced the adoption of open innovation 
strategies in pharmaceutical companies? 
b) Which strategies do firms adopt for new drug research?  
c) How do firm resources and competencies influence the adoption of open 
innovation strategies? 
 
Research approach 
The Indian pharmaceutical industry dealing with contemporary issues entails posing of 
ÔwhatÕ and ÔhowÕ or ÔwhyÕ questions, and this provides a rationale to pursue case study 
research design (Gummesson, 2007). The research framework leads to qualitative case 
study-based research design and the primary data collection mode was semi-structured 
interviews. The secondary data for the case study companies was collected through 
company websites, annual reports and cross checked with two key online pharma news 
magazines Ð ÔExpress PharmaÕ and ÔPharma BizÕ and own research. The information on 
collaborations used for analysis excludes marketing or technology agreements related to 
generics business. It only includes new drug discovery and development collaborations.  
Primarily, in the Indian new drug research landscape there are 10-12 established 
firms involved in new drug research business (Chowdhary, 2010). The product patent 
regime had attracted not only incumbent firms but also startup companies into the new 
drug research business. There is no published data on the number of startups however 
extensive secondary research and interviews revealed an estimate of six to eight startup 
companies involved in the research of small molecules in India. In this study, eight 
pharmaceutical companies engaged in new drug research of small molecules are chosen 
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to understand their unique contexts and experiences. The case selection focused on two 
categories of firms, established and startups.  
1) Case Companies - Established firms  
¥ Dr. Reddy's Laboratories Ltd. 
¥ Lupin Limited   
¥ Piramal Life Sciences (previously Nicholas Piramal)  
¥ Ranbaxy Laboratories (now Sun Pharma) 
2) Case Companies - Startups  
¥ Advinus Therapeutics Limited   
¥ Curadev Pharma Private Limited 
¥ Invictus Oncology Pvt. Limited   
¥ Lifecare Innovations  
The selection of startup companies allowed maximum variation in cases and allowed 
to gain an understanding on the differences between cases (Flyvbjerg, 2006). Startups 
are companies formed in 2005 or after and have sales revenues less than $50 mn. 
Empirical evidence is drawn from 50 semi-structured interviews with senior 
management executives of pharmaceutical companies, academics, public research 
scientists and pharmaceutical experts.  
 
Table 2:  Resource profile of case study firms 
Sample Type Year of start 
of new drug 
research 
operations 
Technological 
Assets 
(Compounds 
in pipeline) 
Financial 
Assets 
Complementary Assets Specific Assets 
Established 
firms 
 
Pre-2005 Upto 20 in 
different 
stages of drug 
research 
 
$1780 
million - 
$2123 
million 
Manufacturing locations 
abroad 
Well entrenched sales and 
distribution channels in 
India 
 
R&D centers in India 
and abroad 
Equipped with 
sophisticated 
facilities 
 
Startups 2005 and 
later 
(1- 15) mostly 
in early stages 
of new drug 
research 
$24 million 
to unreported 
Limited/ No 
manufacturing/marketing 
capabilities 
R&D centers in 
India. Limited 
instruments and lab 
facilities 
 
Findings 
The Indian pharmaceutical sector backed by generic drug business is estimated to be 
USD 16.7 bn in 2014 and accounts for almost 10% of global drug production by 
volume. The Indian pharmaceutical sector is characterized by three features a) 
domination of generic business (accounts for 76% of total medicine sales) b) diversified 
market with 10 large firms dominating 40% of the market c) low R&D expenditure for 
companies in new drug research (less than 9% of net sales; significantly lower than the 
global average 17% of sales turnover) (Tripp, 2012, Business Monitor International, 
2012, Srinivas, 2004). During the process patent regime (1970 Ð 2005), Indian firms 
primarily relied on their in-house expertise and followed a traditional closed R&D 
model. The interactions with public research labs and universities were limited to 
testing and validating of research results and funding of academic projects. 
Collaborations with multinational companies were either for in-licensing of technology 
or marketing agreements to gain access in different countries. 
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With the advent of new drug research in India, companies soon realized that new 
drug is complex, difficult and risky (Interview data) and technical considerations like 
safety, effectiveness and potential side effects play a deciding role in the progress of the 
drug compound (Arora et al., 2009). Globally, pharmaceutical research and 
development is commonly characterized by ten years or more research and development 
work (Drucker, 1985) and has prominent two stages - drug discovery and drug 
development. Despite new process strategies to make the new drug development 
effective, the cost of new drug development is more than one billion dollar (Tufts, 2010,!
Tripp, 2012). Though the cost of new drug development is relatively low in India, 
regulatory hindrances in conducting animal research and clinical trials delay the process 
and increase the costs (Interview data). The limited resources and capabilities of Indian 
companies coupled with the risky nature of business pose a big challenge to conduct 
new drug research. 
Preliminary findings have revealed that the two primary reasons why companies 
pursue open innovation strategies are to get a) technical competencies and b) funding. 
This is further illustrated with examples from our cases, which outlines the idiosyncratic 
pathways adopted by firms for new drug research.  
 
Technical (competencies) collaborations 
In the Indian pharmaceutical milieu, most of the technical collaborations take place at 
the pre-discovery stage or drug discovery stage to gain wider access to scientific talent 
and opinion. Project complexities, goals, stage of the project, internal expertise, project 
feasibility and strength of the external party, have emerged to be the key factors, which 
govern technical collaborations. ÒMy belief is that if something positive comes up here, 
I need to work with a world leader, and if it excites him then my chance of success is 
much higher. In other models, the collaborations are done depending if we require 
certain technologies or certain targets to be validated, we would directly link up either 
with a contract research firm or with a firm in a collaborative mannerÓ (Interview data, 
Established firm).  
i. In-licensing strategy 
     Established companies with enough financial resources engage in, in-licensing 
strategy to fill their pipelines with drug compounds. Ranbaxy Laboratories (now 
Sun Pharma) was the first company in India to develop and launch a new 
chemical entity (NCE) drug ÔSynriamÕ for malaria. The new chemical entity 
Ôarterolane maleateÕ in the drug was discovered by a collaborative drug discovery 
project funded by the Medicines for Malaria Venture (MMV), involving 
researchers from the US, UK, Switzerland and Australia. Ranbaxy in-licensed this 
compound from MMV at drug development stage with a worldwide, royalty-free 
licence for this compound. 
Startup companies limited by their finances use various other strategic options to in-
license exciting research work. ÒWe are open to in-licensing if there are any interesting 
molecules but being a startup company we cannot pay millions of dollars that large 
pharma can payÓ (Interview data - Startup firm). Invictus Oncology, a startup company, 
has been novel in its approach of partnering with the scientific community. It has 
partnered with India Innovation Research Center (IIRC), a not for profit virtual research 
institute, which has researchers and scientists from all over the globe. The company 
hopes to take forward any research output, which comes out of this partnership.  
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ii.  Collaborative R&D Strategy 
      Both established and startup companies seek collaboration at the drug discovery 
stage though the modes of interaction may vary. Piramal Life Sciences had 
effectively used different types of collaborative R&D to gain technical 
competencies at different stages of the project. The company entered into a 
research consortium with nine public research institutes to screen molecules from 
a repository of 14,000 cultures to identify chemical entities. The company then 
took up three new chemical entities for further development and entered into 
many research pacts with various organizations such as Anna University, Indian 
Institute of Science and a German company Pierre Fabre, to screen and identify 
potential molecules while retaining the rights to commercialize any products 
coming out the collaboration. Curadev, a startup company has entered into a 
knowledge based collaboration with University of Greenwich to create novel 
process improvements for select pharmaceuticals. 
Firms engage in open innovation either to in-license a molecule or technology or to 
engage in interactions with the scientific community. In the in-licensing mode, the 
company engages in, in-house R&D once it has the IP rights of the molecule. In the 
collaborative mode, most of the agreements are formalized in such a way to enable the 
firm to retain ownership of the IP however, there are some joint collaboration deals 
wherein the IP is jointly owned and agreed with the partners. ÒIt varies, sometimes we 
have an agreement where we are testing the downstream assays of say a given 
compound and then the IP is shared. Supposing we are taking the help of a chemist in 
designing the compound, then whatever is being synthesized the IP belongs to the 
companyÉ. the third model is that if IP is generated, we will have a separate 
agreement where both the parties will come together and form the clauses of that 
agreement.Ó (Interview data - Startup firm) 
 
Financial Collaborations 
Unlike technical collaborations there is a stark difference in the strategies adopted by 
established firms and startup companies. Established firms seek financial collaborations 
primarily during the drug development stage. The risk for late stage failures and the 
development cost of the drug is too exorbitant to be funded solely by a firm.  Startups 
engage in collaboration to seek financial help at all stages of drug research.  
i. Collaborative R&D through public-private partnership 
     Lupin partnered with four public research institutions to discover a new chemical 
entity LL3858 named Sudoterb for the treatment of tuberculosis. The clinical 
trials for this molecule is being supported by the Indian government under a 
public initiative scheme New Millennium Indian Technology Leadership 
Initiative (NMITLI). The company has also sought financial support in the 
clinical development of two more NCEs in the area of migraine and psoriasis. In 
yet another public initiative, the Department of Science and Technology 
supported the clinical development of the new chemical entity Synriam, which 
was launched by Ranbaxy Laboratories in 2013. Startup companies avail of R&D 
grants and soft loan schemes more frequently to get support in different stages of 
drug discovery and development.  
ii. Collaborative R&D with multinational companies (MNC) 
     Indian firms also collaborate with MNCs for drug development and to leverage 
the complementary marketing and distribution assets overseas for product launch  
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     in case the drug candidate moves successfully across different stages. Advinus 
Therapeutics, a startup firm has a multi-year collaborative deal with Merck to 
discover and develop the drugs till preclinical stage. Merck would make upfront 
and milestone based payments while retaining the rights to undertake the clinical 
development and marketing of the drug. A startup company, Curadev entered into 
a licensing deal with US pharmaceutical company to discover drugs till the 
candidate selection stage and then transfer it to the firm at the clinical 
development stage in exchange for milestones and royalties.  
iii. Out-licensing Strategy: Though out-licensing of a drug compound can be done at 
any stage however, Indian firms prefer to out-license the molecule at the clinical 
development stage. When Dr. ReddyÕs out-licensed its two diabetes molecules in 
1997 to NovoNordisk, it created history as this was the first time an Indian 
company had developed a new chemical entity in-house and made it ready for 
out-licensing.  The molecules failed during the clinical trials nonetheless it opened 
the doors to pursue out-licensing as a viable strategy.  
ÒWe have several molecules in the clinical trials now as you can see in our website 
and the annual reportÉ. we will be engaged in out-licensing of our molecules (means 
basically IP) to big pharma for a price, so they take it up forward for filing and 
approvals and commercializationÓ (Interview data, Established firm). 
ÒEarlier our goal was to discover a molecule, develop it into a drug within India, but 
over the period of years we have changed this pattern.  In the last two years, we started 
trying to package molecules, at different levels for out-licensingÉI think the company 
realized that the financial implications of developing a molecule although 40% lower in 
India as per global estimate, it is still very huge for an Indian pharma to sustain for a 
long timeÓ (Interview data, Established firm). 
Startup companies which have drug compounds in early stages of new drug resarch 
have emphasised that this is an important strategy, which they would consider in the 
next phases. Startup companies also engage with universities and public research to 
avail of instrumentation and testing facilities and enter into collaborations for venture 
funding. 
 
Conclusion 
The strategic pathways adopted by firms are idiosyncratic however, common patterns 
can be observed within the two case company groups, i.e. one among the established 
firms and other one among startups. The established companies engage in technical 
collaborations either at pre-discovery stage to in-license molecules or during the drug 
discovery stage to seek answers to specific questions.  Their primary strategy is to rely 
on their own internal drug discovery programs and engage in collaborative risk sharing 
model or out-licensing deals only during the drug development phase.  On the other 
hand, startups engage in different collaborative deals throughout the drug research 
process. In open innovation parlance, this suggests that firms use open innovation 
perspective as a means to achieve their goals. Within the dynamic capabilities 
framework, the findings suggest that firms are driven by their internal competencies, 
financial resources, and other assets to adopt various open innovation strategies. A 
plausible explanation lies in the concept of dynamic firm capabilities, which evaluates 
the role of firm resource profile in charting the course of firm behavior (Nelson, 1991, 
Insead and Eisenhardt, 2001, Teece et al., 1997). 
The discussion about the Indian pharmaceutical industry contributes to our 
understanding of how the companies have adapted strategies to suit their resources and 
competencies. The new drug research business has been tumultuous in the Indian 
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pharmaceutical milieu. Two established companies in the cases - Ranbaxy Laboratories 
and Piramal Life Sciences have exited from the new drug research business. Dr. 
ReddyÕs Laboratories has scaled down its new drug research operations after some 
initial setbacks. The reasons for downscaling of drug research activities are manifold 
but by drawing on these cases, this paper makes an argument for the dynamic 
interaction between strategic action and resource profile in constraining extraneous 
factors. In providing directions for strategic research (Priem et al., 2013) emphasised 
the need for future research studies linking the resource side and environment contexts 
of the firm. In this way, the study hopes to make a contribution to the dynamic 
capabilities literature. 
With regards to open innovation, the cases deepen our understanding of inter-firm 
heterogeneity in charting open innovation strategies. Regarding strategic management 
research, this study highlights the firm level constraints for technological innovation in 
a developing country. In this way, this article is also of particular interest from a 
business process perspective to practitioners and researchers. Lastly in the Indian 
context, this study aims to extend the prior research work on Indian pharmaceutical 
industry. (Sampath, 2008) has detailed the emergent strategies in the Indian 
pharmaceutical landscape in response to the product patent regime. In yet another study, 
(Athreye et al., 2009) has demonstrated the dynamic capabilities of four large Indian 
pharmaceutical firms to adapt itself to different environmental changes by adapting its 
resource and strategies. However, studies comparing open innovation strategies adopted 
by firms for new drug research mediated by resource position of a firm has not been 
studied before and in this way the paper hopes to make an original contribution.   
The innovative environment in the Indian pharmaceutical sector is rapidly changing 
with new firms evolving and old firms disappearing from the innovation space. The 
level of openness and the strategic flexibility suggest that those firms will successfully 
innovate that cope with these critical challenges.  
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